(Q24236814)

4

0 references

Rachel Churchill

7

0 references

Atsuo Nakagawa

Atsuo Nakagawa

3

0 references

Hugh McGuire

6

Hugh McGuire

0 references

Toshi A Furukawa

8

Toshi A Furukawa

0 references

Ichiro M Omori

1

Ichiro M Omori

0 references

Norio Watanabe

2

Cochrane Database of Systematic Reviews

Norio Watanabe

0 references

language of work or name

English

0 references

publication date

2010

0 references

published in

0 references

issue

3

0 references

page(s)

CD006114

0 references

cites work

Escitalopram versus other antidepressive agents for depression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

Effectiveness of paroxetine in the treatment of acute major depression in adults: a systematic re-examination of published and unpublished data from randomized trials

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

Early onset of selective serotonin reuptake inhibitor antidepressant action: systematic review and meta-analysis

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

Fluoxetine versus other types of pharmacotherapy for depression

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

A rating scale for depression

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

Pharmaceutical industry sponsorship and research outcome and quality: systematic review

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

Bias in meta-analysis detected by a simple, graphical test

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

Sertraline versus other antidepressive agents for depression

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

St John's wort for major depression

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

Amitriptyline for depression

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

Selective serotonin reuptake inhibitors (SSRIs) versus other antidepressants for depression

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

Antidepressants for depressed elderly

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events?

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

Measuring inconsistency in meta-analyses

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

The MOS 36-ltem Short-Form Health Survey (SF-36)

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

A comparative study of the efficacy and safety profiles between fluvoxamine and nortriptyline in Japanese patients with major depression

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

Milnacipran and selective serotonin reuptake inhibitors in major depression

19 March 2017

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

19 March 2017

https://api.crossref.org/works/10.1002%2F14651858.CD006114.PUB2

Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

Imputing missing standard deviations in meta-analyses can provide accurate results

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

Meta-analyses involving cross-over trials: methodological issues

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

Detecting skewness from summary information

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

Improving the quality of reporting of randomized controlled trials. The CONSORT statement

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

A New Depression Scale Designed to be Sensitive to Change

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

Mirtazapine versus other antidepressants in the acute-phase treatment of adults with major depression: systematic review and meta-analysis.

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

Evaluation of networks of randomized trials

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patients.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

Are all antidepressants really the same? The case of fluoxetine: a systematic review.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

Industry sponsorship and financial conflict of interest in the reporting of clinical trials in psychiatry

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

The economic burden of depression in the US: societal and patient perspectives

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

An analysis of the effect of funding source in randomized clinical trials of second generation antipsychotics for the treatment of schizophrenia

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

Prevalence and outcomes of pharmaceutical industry-sponsored clinical trials involving clozapine, risperidone, or olanzapine.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

Are we going to increase the use of antidepressants up to that of benzodiazepines?

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

Australian and New Zealand clinical practice guidelines for the treatment of depression

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

"Wish bias" in antidepressant drug trials?

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

Industry sponsorship and authorship of clinical trials over 20 years

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

The economic burden of depression in the United States: how did it change between 1990 and 2000?

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

Meta-analysis of effects and side effects of low dosage tricyclic antidepressants in depression: systematic review

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

CPT performance in major depressive disorder before and after treatment with imipramine or fluvoxamine

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

Can we individualize the 'number needed to treat'? An empirical study of summary effect measures in meta-analyses

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

Selective serotonin reuptake inhibitors versus tricyclic and heterocyclic antidepressants: comparison of drug adherence

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

A systematic review of newer pharmacotherapies for depression in adults: evidence report summary

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines. British Association for Psychopharmacology

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

Effectiveness of antidepressants. Meta-analysis of dose-effect relationships in randomised clinical trials

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

Systematic review and guide to selection of selective serotonin reuptake inhibitors

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

SSRIS versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

Selective activation of postsynaptic 5-HT1A receptors induces rapid antidepressant response.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

Overview of the pharmacokinetics of fluvoxamine

27 September 2017

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

27 September 2017

https://api.crossref.org/works/10.1002%2F14651858.CD006114.PUB2

Fluvoxamine maleate in the treatment of depression: a single-center, double-blind, placebo-controlled comparison with imipramine in outpatients

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

Efficacy of acute treatment for geriatric depression

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

Drug treatment of depression in the frail elderly: discussion of the NIH Consensus Development Conference on the Diagnosis and Treatment of Depression in Late Life

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

Clinical pharmacokinetics of fluvoxamine

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

Fluvoxamine. A review of its safety profile in world-wide studies.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

Global assessment of functioning. A modified scale

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

A double-blind placebo-controlled study of fluvoxamine and imipramine in out-patients with primary depression

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

Clinical trials of fluvoxamine vs chlorimipramine with single and three times daily dosing

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

A double-blind comparative study of the clinical efficacy of fluvoxamine and chlorimipramine

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

A double-blind controlled clinical trial comparing fluvoxamine with imipramine

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

Diagnostic Criteria for Use in Psychiatric Research

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

Fluvoxamine in the treatment of the older depressed patient; double-blind, placebo-controlled data.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

Serotonin reuptake blockers in vitro and in vivo.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

The effects of psychomotor performance of fluvoxamine versus mianserin in depressed patients in general practice

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

A Review of Fluvoxamine and its Uses in Depression

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

A consumer's guide to subgroup analyses

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

Research diagnostic criteria: rationale and reliability

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

Fluvoxamine, a specific 5-hydroxytryptamine uptake inhibitor

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

Interest of a loading dose of milnacipran in endogenous depressive inpatients. Comparison with the standard regimen and with fluvoxamine

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

Clinical efficacy of milnacipran: placebo-controlled trials.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

Onset of response in relation to outcome in depressed outpatients with placebo and imipramine

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

Response to total sleep deprivation before and during treatment with fluvoxamine or maprotiline in patients with major depression--results of a double-blind study.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

Chronicity of depressive episode in relation to antidepressant-placebo response

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

Fluvoxamine: a review of the controlled trials in depression

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

Serotonin reuptake inhibition vs. norepinephrine reuptake inhibition: a double-blind differential-therapeutic study with fluvoxamine and oxaprotiline in endogenous and neurotic depressives

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

Health of the Nation Outcome Scales (HoNOS). Research and development

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability.

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

A double-blind comparison of fluvoxamine and paroxetine in the treatment of depressed outpatients

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

Efficacy and tolerability of citalopram in comparison with fluvoxamine in depressed outpatients: a double-blind, multicentre study. The LUCIFER Group.

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

A comparison of fluvoxamine and fluoxetine in the treatment of major depression

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

Cardiovascular effects of imipramine, fluvoxamine, and placebo in depressed outpatients

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

A double-blind comparison of fluvoxamine, imipramine and placebo in depressed patients

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

Fluvoxamine and clomipramine in depressed patients. A double-blind clinical study.

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

A double-blind placebo-controlled study of fluvoxamine and imipramine in depression.

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

Treatment strategy in depression. I. Non-tricyclic and selective reuptake inhibitors in resistant depression: a double-blind partial crossover study on the effects of oxaprotiline and fluvoxamine.

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

A double-blind comparison of fluvoxamine and dothiepin in the treatment of major affective disorder

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

Use of a standardized documentation system (BLIPS/BDP) in the conduct of a multicenter international trial comparing fluvoxamine, imipramine, and placebo.

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

A double-blind, randomized comparison of fluvoxamine with mianserin in depressive illness

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

Fluvoxamine in the treatment of tricyclic-resistant depression.

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

A functional-dimensional approach to depression: serotonin deficiency as a target syndrome in a comparison of 5-hydroxytryptophan and fluvoxamine

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

Fluvoxamine versus desipramine: comparative polysomnographic effects.

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

Therapeutic sleep deprivation and antidepressant medication in patients with major depression.

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

Changes in daily life experience associated with clinical improvement in depression.

30 May 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006114.PUB2

Antidepressant efficacy and tolerability of milnacipran, a dual serotonin and noradrenaline reuptake inhibitor: a comparison with fluvoxamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006114.PUB2

Fluvoxamine versus fluoxetine in major depressive episode: a double-blind randomised comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006114.PUB2

Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006114.PUB2

24-Hour motor activity after treatment with imipramine or fluvoxamine in major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006114.PUB2

Effects of imipramine, fluvoxamine and depressive mood on autonomic cardiac functioning in major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006114.PUB2

Noradrenergic function and clinical outcome in antidepressant pharmacotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006114.PUB2

Sertraline versus fluvoxamine in the treatment of elderly patients with major depression: a double-blind, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006114.PUB2

Neuroendocrine (HPA axis) and clinical correlates during fluvoxamine and amitriptyline treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006114.PUB2

Plasma levels of catecholamine metabolites predict the response to sulpiride or fluvoxamine in major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006114.PUB2

Fluvoxamine as effective as clomipramine against symptoms of severe depression: results from a multicentre, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006114.PUB2

Diagnosis at the first episode to differentiate antidepressant treatment responses in patients with mood and anxiety disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006114.PUB2

A critical examination of the sensitivity of unidimensional subscales derived from the Hamilton Depression Rating Scale to antidepressant drug effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006114.PUB2

Cardiovascular effects of fluvoxamine and maprotiline in depressed patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006114.PUB2

Stressful life events and coping styles in relation to dysthymia and major depressive disorder: variations associated with alleviation of symptoms following pharmacotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006114.PUB2

Further evidence of a combined effect of SERTPR and TPH on SSRIs response in mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006114.PUB2

Comparison of two-phase treatment with imipramine or fluvoxamine, both followed by lithium addition, in inpatients with major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006114.PUB2

A double-blind randomized study comparing imipramine with fluvoxamine in depressed inpatients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006114.PUB2

Gender differences in the clinical effects of fluvoxamine and milnacipran in Japanese major depressive patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006114.PUB2

Reboxetine versus other antidepressive agents for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006114.PUB2

Paroxetine versus other anti-depressive agents for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006114.PUB2

Venlafaxine versus other anti-depressive agents for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006114.PUB2

Association between unreported outcomes and effect size estimates in Cochrane meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006114.PUB2

Suicidality in pediatric patients treated with antidepressant drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006114.PUB2

Citalopram versus other anti-depressive agents for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006114.PUB2

Indirect comparisons: the mesh and mess of clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006114.PUB2

Differentiating moderate and severe depression using the Montgomery-Asberg depression rating scale (MADRS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006114.PUB2

Milnacipran versus other anti-depressive agents for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006114.PUB2

Duloxetine versus other anti-depressive agents for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006114.PUB2

Symptom profiles of depression among general medical service users compared with specialty mental health service users

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006114.PUB2

Plasma concentrations of fluvoxamine and maprotiline in major depression: implications on therapeutic efficacy and side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006114.PUB2

Imputing response rates from means and standard deviations in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006114.PUB2

The World Health Organization quality of life assessment (WHOQOL): Development and general psychometric properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006114.PUB2

Evaluation of double-blind comparison of fluvoxamine and paroxetine in the treatment of depressed outpatients in menopause transition.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

Antidepressant drug consumption and public health indicators in Italy, 1955 to 2000.

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

Depression-free days as a summary measure of the temporal pattern of response and remission in the treatment of major depression: a comparison of venlafaxine, selective serotonin reuptake inhibitors, and placebo.

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

Comparative efficacy and tolerance of fluvoxamine and amitriptyline in the treatment of moderate and severe depression in mental hospital

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

Antidepressant efficacy in relation to item analysis and severity of depression: a placebo-controlled trial of fluvoxamine versus imipramine

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

A placebo-controlled inpatient comparison of fluvoxamine maleate and imipramine in major depression.

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

Multicenter study comparing efficacy and tolerance of moclobemide and fluvoxamine in hospitalized and ambulatory patients with severe depressive episodes

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171125

Prolactin response to d-fenfluramine in major depression before and after treatment with serotonin reuptake inhibitors

29 November 2018

1 reference

12 December 2020

Creation of a clinical classification. International statistical classification of diseases and related health problems--10th revision, Australian modification (ICD-10-AM)

1 reference

12 December 2020

Venlafaxine Versus Fluvoxamine in the Treatment of Delusional Depression

1 reference

12 December 2020

Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association

1 reference

12 December 2020

SSRIs versus other antidepressants for depressive disorder

1 reference

12 December 2020

Four-year follow-up study of sertraline and fluvoxamine in long-term treatment of unipolar subjects with high recurrence rate

1 reference

12 December 2020

Care utilization and outcome of DSM-III-R major depression in the general population. Results from the Netherlands Mental Health Survey and Incidence Study (NEMESIS)

1 reference

12 December 2020

Network meta-analysis for indirect treatment comparisons

1 reference

12 December 2020

Frequency of positive studies among fixed and flexible dose antidepressant clinical trials: an analysis of the food and drug administration summary basis of approval reports

1 reference

12 December 2020

Perspectives in clinical psychopharmacology of amitriptyline and fluvoxamine. A double-blind study in depressed inpatients

1 reference

12 December 2020

Fluvoxamine in the treatment of depressive illness. A series of double-blind hospital based comparative studies carried out in the UK

1 reference

12 December 2020

A comparison of fluvoxamine, fluoxetine, sertraline and paroxetine examined by observational cohort studies

1 reference

12 December 2020

Efficacy and tolerability of moclobemide compared with fluvoxamine in depressive disorder (DSM III). A French/Swiss double-blind trial

1 reference

12 December 2020

Remission rates with milnacipran 100 mg/day and 150 mg/day in the long-term treatment of major depression

1 reference

12 December 2020

Effect of antidepressant treatment on platelet 5-HT content and relation to therapeutic outcome in unipolar depressive patients

1 reference

12 December 2020

A double-blind, randomised comparison of fluvoxamine with dothiepin in the treatment of depression in elderly patients

1 reference

12 December 2020

Deuterium-labelled p-tyramine challenge test and phenolsulfotransferase activity in depressed patients--failure to replicate decreased p-tyramine conjugation in depression

1 reference

12 December 2020

Randomized double-blind study of fluvoxamine and maprotiline in treatment of depression

1 reference

12 December 2020

Double-blind comparative multicentre study of fluvoxamine and mianserin in the treatment of major depressive episode in elderly people

1 reference

12 December 2020

Early predictors of two month response with mianserin and selective serotonin reuptake inhibitors and influence of definition of outcome on prediction

1 reference

12 December 2020

A double-blind, placebo-controlled trial of fluvoxamine versus imipramine in outpatients with major depression

1 reference

12 December 2020

The role of neuropharmacologic selectivity in antidepressant action: fluvoxamine versus desipramine

1 reference

12 December 2020

Fluvoxamine and imipramine in the treatment of depressive patients: a double-blind controlled study

1 reference

12 December 2020

The efficacy of selective serotonin re-uptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants

1 reference

12 December 2020

Effects of desipramine and fluvoxamine treatment on the prolactin response to tryptophan. Serotonergic function and the mechanism of antidepressant action

1 reference

12 December 2020

Fluvoxamine, imipramine, and placebo in the treatment of depressed outpatients: effects on depression

1 reference

12 December 2020

Pituitary-adrenocortical hyperfunction and intolerance to fluvoxamine, a selective serotonin uptake inhibitor

1 reference

12 December 2020

Variability of response to lithium augmentation in refractory depression

1 reference

12 December 2020

Treatment of major affective disorder with fluvoxamine

1 reference

12 December 2020

Fluvoxamine and imipramine: results of a long-term controlled trial

1 reference

12 December 2020

Repolarisation disturbances in the ECG under antidepressant drugs. A comparison of two drugs, differing in chemical structure and pharmacological profile (author's transl)

1 reference

12 December 2020

Fluvoxamine and chlorimipramine in endogenous depression

1 reference

12 December 2020

A double-blind clinical trial of fluvoxamine and imipramine in patients with primary depression

1 reference

12 December 2020

Fluvoxamine maleate, a serotonergic antidepressant; a comparison with chlorimipramine

1 reference

12 December 2020

Effect of cigarette smoking on fluvoxamine pharmacokinetics in humans

1 reference

12 December 2020

Fluvoxamine and clomipramine in depressed hospitalised patients: results from a randomised, double-blind study

1 reference

12 December 2020

A comparison of the effects of imipramine and fluvoxamine on the thyroid axis.

1 reference

12 December 2020

The effect of amitriptyline, doxepin, fluvoxamine, and paroxetine treatment on heart rate variability

1 reference

12 December 2020

Are SSRI antidepressants a clinically homogeneous class of compounds?

1 reference

12 December 2020

The efficacy of fluvoxamine in patients with severe depression

1 reference

12 December 2020

Effect of fluvoxamine, imipramine and placebo on catecholamine function in depressed outpatients

1 reference

12 December 2020

Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients

1 reference

12 December 2020

Electrocardiographic findings during extended clinical trials of fluvoxamine in depression: one years experience

1 reference

12 December 2020

Fluvoxamine versus imipramine and placebo: a double-blind comparison in depressed patients

1 reference

12 December 2020

1 reference

12 December 2020

[Maprotiline versus fluvoxamine: comparison of their effects on the hypothalamo-hypophyseal-thyroid axis]

1 reference

12 December 2020

Cardiac side-effects of two selective serotonin reuptake inhibitors in middle-aged and elderly depressed patients

1 reference

12 December 2020

SSRIs versus tricyclic antidepressants in depressed inpatients: A meta-analysis of efficacy and tolerability

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006114.PUB2

7 January 2021

inferred from DOI database lookup

Detection of symptomless postoperative deep vein thrombosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006114.PUB2

7 January 2021

inferred from DOI database lookup

Guidelines for choice of selective serotonin reuptake inhibitor in depressive illness

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006114.PUB2

7 January 2021